Clinical-stage biopharmaceutical
company focused on developing novel hydroxyl
dendrimer therapeutics (HDTs) to treat unmet
medical needs in neurology, ophthalmology,
inflammatory diseases and oncology.
Three clinical stage programs are ongoing with data readouts in 2023.